Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was quoted in multiple publications on the topic of the FDA’s new regulatory guidelines, released on December 7, 2017, for digital health devices and clinical decision support.

Following is an excerpt from FierceHealthcare, “After A 6-Year Wait, FDA’s Clinical Decision Support Guidelines Get a Mixed Reaction,” by Evan Sweeney.

It’s been six years since the Food and Drug Administration said it would begin developing guidance for clinical decision support (CDS) software.

Now that the guidance is finally here, some industry experts are feeling slightly underwhelmed. For Bradley Merrill Thompson, a medical device attorney with Epstein Becker & Green in Washington, D.C., the FDA’s guidance “stopped at the edge” of the regulatory framework outlined in the 21st Century Cures Act, which carves out an oversight exemption for software that can be independently reviewed by physicians.

“I’m afraid I was expecting much more,” Thompson wrote in an email to FierceHealthcare. “I was expecting a guidance that focuses on risk, rather than simply explaining the statutory language in slightly greater detail.”

That reluctance to embrace a risk-based approach to CDS software is Thompson’s biggest complaint. He argues that software that predicts the likelihood of a migraine, for example, has a far lower risk to patient safety than a tool that recommends a specific chemotherapy treatment, which could be a life or death decision.

Instead, in its draft recommendations issued on Thursday, the agency fell in line with the approach outlined in Cures, devoting most of its focus to the transparency of CDS software and the ability for physicians and patients to understand the basis for the software’s recommendation.

“What I think many of us in industry were hoping for was an effort by FDA to distinguish high from low risk as a basis for regulation,” he wrote. “We didn’t get that. Worse, it appears based on the guidance that FDA is not interested in drawing that line.”

Related reading:

Jump to Page

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.